ライフサイエンスコーパス: pancreaticobiliary

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 secretion and responses to feeding, we used pancreaticobiliary and intestinal cannula to divert bile

2 ith paired peripheral CTCs, in patients with pancreaticobiliary cancers (PBCs).

3 igation of the genetic alterations common to pancreaticobiliary cancers and aid the understanding of

4 atic and biliary manifestations of AIP mimic pancreaticobiliary cancers.

5 tablishing a strategy to distinguish it from pancreaticobiliary cancers.

6 nt prognosis; two, those with histomolecular pancreaticobiliary carcinoma with LN metastases who had

7 tients with renal cell carcinoma (7 months), pancreaticobiliary carcinomas (3, 5, and 5 months), mela

8 was performed in 265 patients with suspected pancreaticobiliary disease and in 35 control patients wi

9 ier RARE MRCP enables accurate evaluation of pancreaticobiliary disease and obviates ERCP in some pat

10 Pancreaticobiliary disease occurred in 20 of 255 transpl

11 Pancreaticobiliary disease occurs 17.4 times (95% CI, 9.

12 tion of hospitalization for the treatment of pancreaticobiliary disease was longer for patients who r

13 Risk factors assessed at presentation of pancreaticobiliary disease were weight change after tran

14 uracy of 100% in determining the presence of pancreaticobiliary disease, the presence and level of bi

15 he diagnostic accuracy of MR examinations of pancreaticobiliary disease.

16 ompare immune cell infiltration of different pancreaticobiliary diseased tissues (PDAC, ampullary car

17 This review aims to record pancreaticobiliary endoscopic ultrasound (EUS) and other

18 Pancreaticobiliary IPNB expresses MUC1 and is more frequ

19 ients (nonpancreaticobiliary, LN positive or pancreaticobiliary, LN negative) who had an intermediate

20 iliary brushing specimens from patients with pancreaticobiliary masses.

21 vided histopathologically into intestinal or pancreaticobiliary (PB) types, which may more accurately

22 Patients with a histomolecular pancreaticobiliary phenotype (CDX2 negative, MUC1 positi

23 absorption), and (3) if the inhibitor alters pancreaticobiliary secretions or intraluminal pH.

24 olymeric nutrients, potential stimulation of pancreaticobiliary secretions, secretion of humoral medi

25 To determine trends in pancreaticobiliary stents over the past 12-18 months.

26 Endoscopic placement of pancreaticobiliary stents plays an important role in the

27 following pancreaticoduodenectomy (PD) in a pancreaticobiliary surgical specialty unit.

28 s a non-surgical approach to diseases of the pancreaticobiliary system that dates back to the late 19

29 e found at significantly higher frequency in pancreaticobiliary than intestinal, gastric or oncocytic

30 After failed ERCP, MRCP delineated the pancreaticobiliary tract and helped determine therapeuti

31 A significantly higher proportion of pancreaticobiliary tumors compared with intestinal tumor

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。